Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (15933)	8/4/2002 1:02:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bluegreen, whatever happened to Microcide? Remember when it was popular and the unlearned and unwashed were told by those in the know that small molecules were the place to be and not proteins?

To: Bluegreen who wrote (15933)	8/5/2002 3:27:12 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Recent psoriasis report is from xoma material, Dna material is still ongoing 500 subjects expected completion by end of the year allowing filing. xomaDna are also running another trial to lear how to get patients OUT of the drug, kind of a weaning dosages trial to avoid roaring back disease. Baxtard sepsis trial, well the pick up of Xigris for treatment is slow, it could be they do not need to go in combo, IF THEY START SOON...soon soon soon...yeah soon soon soon !!!

To: Bluegreen who wrote (15933)	8/7/2002 6:10:44 PM
From: aknahow	Respond to of 17367

An investor presentation per month through November. Bluegreen, do you know of any other biotech that is doing the same? The kicker is that perhaps the FDA filing will have been made before the last one and they will have some real news to talk about. XOMA 2nd Q Conference Call August 15, 1pm PDT, Berkeley, CA Jack Castello September 2002 BioCentury Newsmakers Conference September 5, New York, NY Jack Castello, XOMA Corporate Presentation October 2002 European Society for Medical Oncology Congress October 18-22, Nice, France Johann S. de Bono, MD MRCP (UK) MSc PhD, University of Texas at San Antonio, "Phase I trail of a human-engineered(TM) monoclonal anti-EpCAM antibody, ING-1(heMAb), in patients with advanced adenocarcinomas" UBS Warburg Global Life Sciences Conference October 7-10, New York, NY Jack Castello, XOMA Corporate Presentation November 2002 CIBC World Markets Health Care Conference November 4-6, NY, NY Jack Castello, XOMA Corporate Presentation